Valuation: Biogen Inc.

Market Cap 29.99B 26.07B 24.26B 22.28B 42.07B 2,863B 42.72B 286B 112B 1,425B 113B 110B 4,779B P/E 2026 *
37.2x
P/E 2027 * 17.9x
Enterprise Value 35.07B 30.48B 28.37B 26.05B 49.2B 3,348B 49.96B 334B 131B 1,667B 132B 129B 5,588B EV / Sales 2026 *
3.37x
EV / Sales 2027 * 3.07x
Free-Float
85.97%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week-0.24%
1 month+7.09%
3 months+13.09%
6 months+18.99%
Current year+18.32%
1 week 176.06
Extreme 176.06
189.72
1 month 165.54
Extreme 165.54
193
Current year 134.7
Extreme 134.7
193
1 year 109
Extreme 109
193
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-0.24% - - 29.99B
+3.29%+16.25%+39.81%+2.79% 76.15B
-2.75%+48.50%+48.50%+48.50% 47.83B
+2.72%-9.39%+17.04%+176.83% 48.89B
-3.81%+7.74%-54.57%-54.17% 41.37B
-2.82%+1.57%+59.59%+87.57% 24.23B
-5.35%+1.39%+85.45%-53.41% 21.75B
-1.59%-3.61%-11.53%+150.58% 19.25B
-0.42%+2.89%+74.55%+128.45% 17.14B
-2.50%-4.68%+69.43%+128.76% 15.66B
Average -1.74%+0.92%+36.48%+68.43% 34.69B
Weighted average by Cap. -1.36%+2.84%+30.01%+54.48%

Financials

2026 *2027 *
Net sales 10.41B 9.05B 8.42B 7.73B 14.61B 994B 14.83B 99.3B 38.97B 495B 39.1B 38.24B 1,659B 10.6B 9.22B 8.58B 7.88B 14.88B 1,012B 15.11B 101B 39.69B 504B 39.82B 38.95B 1,690B
Net income 959M 834M 776M 713M 1.35B 91.56B 1.37B 9.15B 3.59B 45.58B 3.6B 3.52B 153B 1.92B 1.67B 1.55B 1.42B 2.69B 183B 2.73B 18.27B 7.17B 91.05B 7.2B 7.04B 305B
Net Debt 5.08B 4.42B 4.11B 3.77B 7.13B 485B 7.24B 48.46B 19.02B 241B 19.08B 18.66B 810B 2.57B 2.23B 2.08B 1.91B 3.6B 245B 3.66B 24.47B 9.61B 122B 9.64B 9.43B 409B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
31/07/26 EUR 177.42 -0.39% 117
30/07/26 EUR 178.12 -6.11% 154
29/07/26 EUR 189.72 +6.66% 390
28/07/26 EUR 177.88 -0.33% 0
27/07/26 EUR 178.46 +0.35% 31
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
202.95USD
Average target price
234.35USD
Spread / Average Target
+15.47%

Quarterly revenue - Rate of surprise